Goals for Epilepsy Clinic Visits Trial
NCT05928598 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152
Last updated 2025-10-17
Summary
The purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the "Epilepsy Visit Planner") have improved outcomes compared to patients that do not receive the tool.
The project's hypotheses are:
* Patients that receive the Epilepsy Visit Planner will have improved patient-provider communication compared to the non-planner group.
* Patients that receive the Epilepsy Visit Planner will have improved quality of life scores.
* The Epilepsy Visit Planner will score highly on process measures of feasibility and acceptability, demonstrating suitability for future larger scale study.
Additionally, there is a related survey project that is not part of the clinical trial and will not be included in this registration information.
Conditions
- Drug Resistant Epilepsy
Interventions
- BEHAVIORAL
-
Survey questionnaires
Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
- BEHAVIORAL
-
Epilepsy Visit Planner
Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner. Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
- BEHAVIORAL
-
Questionnaires for Providers
Providers will be asked to complete a survey after the clinic visit for the intervention group.
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
collaborator NIH - lead OTHER
Principal Investigators
-
Chloe Hill, MD · University of Michigan
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-27
- Primary Completion
- 2026-09-01
- Completion
- 2027-01-01
Countries
- United States
Study Locations
More Related Trials
-
Evaluation and Treatment of Patients With Epilepsy
NCT00013845 ·Status: TERMINATED
-
Human Epilepsy Project 3
NCT05374928 ·Status: ACTIVE_NOT_RECRUITING
-
Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
NCT03288129 ·Status: COMPLETED ·Phase: PHASE4
-
Behavioral and Educational Tools to Improve Epilepsy Care
NCT02646631 ·Status: COMPLETED ·Phase: NA
-
Trial for Epilepsy Patients Non-responsive to AEDs Using Medical App
NCT03747705 ·Status: UNKNOWN
-
Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data
NCT05845255 ·Status: RECRUITING
-
Fenfluramine for Adult Dravet Patients
NCT05560282 ·Status: TERMINATED ·Phase: PHASE3
-
NYU Epilepsy Self-Management Study
NCT07087821 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation Of A Mobile Messaging Service In Improving Adherence Of Anti-Seizure Medications
NCT05321641 ·Status: UNKNOWN ·Phase: NA
-
Precision Medicine in the Treatment of Epilepsy
NCT05450822 ·Status: RECRUITING
-
Enhancing Antiepileptic Drug Adherence
NCT02165306 ·Status: COMPLETED ·Phase: NA
-
Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy
NCT02655198 ·Status: UNKNOWN ·Phase: PHASE2
-
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
NCT00144690 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome
NCT03299842 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
NCT05947656 ·Status: RECRUITING ·Phase: NA
-
Adherence to Pharmacological Antiepileptic Treatment in Adolescence
NCT05825807 ·Status: UNKNOWN
-
Study of Antiepileptic Drug Effects on Child Development
NCT00353886 ·Status: COMPLETED
-
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
NCT00351611 ·Status: COMPLETED ·Phase: PHASE4
-
Epilepsy Impact Scale
NCT01833234 ·Status: COMPLETED
-
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
NCT00232596 ·Status: COMPLETED ·Phase: PHASE3
-
Managing Epilepsy Well- WebEase Project
NCT00726076 ·Status: COMPLETED ·Phase: NA
-
Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation
NCT00298818 ·Status: COMPLETED
-
Clinical Utility of the SPEAC® System: A Case Series
NCT03484598 ·Status: UNKNOWN ·Phase: NA
-
Physiologic Effects of Topiramate on Cognition
NCT02884050 ·Status: COMPLETED ·Phase: PHASE1
-
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
NCT05555537 ·Status: UNKNOWN